Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 31;25(1):2358551.
doi: 10.1080/15384047.2024.2358551. Epub 2024 May 30.

NRS2002 score as a prognostic factor in solid tumors treated with immune checkpoint inhibitor therapy: a real-world evidence analysis

Wanfen Tang  1 , Chenghui Li  1 , Dong Huang  2 , Shishi Zhou  1 , Hongjuan Zheng  1 , Qinghua Wang  1 , Xia Zhang  1 , Jianfei Fu  1
Affiliations

NRS2002 score as a prognostic factor in solid tumors treated with immune checkpoint inhibitor therapy: a real-world evidence analysis

Wanfen Tang et al. Cancer Biol Ther. .

Abstract

To observe the antitumour efficacy of programmed death 1 (PD-1) inhibitors in the real world and explore the relationship between NRS2002 score or other clinical characteristics and immunotherapy efficacy, we retrospectively analyzed 341 tumor patients who received immune checkpoint inhibitor (ICI) treatment at one center. A total of 341 solid tumor patients treated with ICIs from June 2018 to December 2021 were retrospectively included in this study. Patient characteristics, ICI responses, and survival status were documented, and the relationships between clinical factors and survival were analyzed. Among all patients, the median progression-free survival (PFS) was 5.8 months, and the median overall survival (OS) was 12.5 months. The Performance Status (PS), NRS2002 score, The Naples Prognostic Score (NPS), Lymphocyte and C-reactive protein ratio (LCR), line of therapy, and nutritional support were significantly related to PFS or OS according to univariate analysis. The median PFS and OS were significantly better in the group without nutritional risk (NRS2002 0-2) than those with nutritional risk (NRS2002 ≥ 3) (PFS: HR = 1.82, 95% CI 1.30-2.54, p value < .001; OS: HR = 2.49, 95% CI 1.73-3.59, p value < .001). Cox regression analysis revealed that the NRS2002 score was an independent prognostic factor for both PFS and OS. The objective response rate (ORR) in the group at nutritional risk was lower than that in the group without nutritional risk (8.33% and 19.71%, respectively, p value = .037). Patients at nutritional risk according to the NRS2002 score at initial treatment had a poorer prognosis than those without nutritional risk. The NRS2002 could be used as a preliminary index to predict the efficacy of immune checkpoint inhibitor therapy.

Keywords: Nutritional Risk Screening (NRS) 2002; Tumor immune checkpoint inhibitor therapy; cancer nutrition; real-world research.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest was reported by the author(s).

Figures

Figure 1.
Figure 1.
The Kaplan-Meier curves of PFS (a) and OS (b).
Figure 2.
Figure 2.
a-j the Kaplan-Meier curves of PFS and OS based on significant clinical factors.
Figure 2.
Figure 2.
(Contiuned).
Figure 3.
Figure 3.
a-f the Kaplan-Meier curves of PFS and OS based on different treatment lines.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Postow MA, Callahan MK, Wolchok JD.. Immune checkpoint blockade in cancer therapy. J Clin Oncol. 2015. Jun 10;33(17):1974–10. doi:10.1200/JCO.2014.59.4358. - DOI - PMC - PubMed
    1. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000. Oct 2;192(7):1027–1034. doi:10.1084/jem.192.7.1027. - DOI - PMC - PubMed
    1. Topalian SL, Hodi FS, Brahmer JR, Gettinger, SN, Smith, DC, McDermott, DF, Powderly, JD, Carvajal, RD, Sosman, JA, Atkins, MB, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012. Jun 28;366(26):2443–2454. - PMC - PubMed
    1. Abdel Hafeez LA, Mansor SG, Zahran AM. Expression of programmed death ligand-1 (PDL-1) in Acute Myeloid Leukemia patients and its relation to post induction response. SECI Oncol J. 2021;9(2):106–111.
    1. Hoos A. Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations. Nat Rev Drug Discov. 2016. Apr;15(4):235–247. doi:10.1038/nrd.2015.35. - DOI - PubMed

Substances

Grants and funding

The study was partially supported by Jinhua Municipal Science & Technology Bureau (grant number 2020-3-028, 2021-3-080).The study was partially supported by Affiliated Jinhua Hospital, Zhejiang University School of Medicine (grant number: JY2020-2-04).

LinkOut - more resources

-